Activation of free fatty acid receptor 1 (FFAR1; also known as G-protein-coupled receptor 40) by fatty acids stimulated glucose-dependent β-cell insulin secretion in preclinical models. Study was carried out to assess whether selective pharmacological activation of this receptor by TAK-875 in patients with type 2 diabetes mellitus improved glycaemic control without hypoglycaemia risk.
Its result was TAK-875 significantly improved glycaemic control in patients with type 2 diabetes with minimum risk of hypoglycaemia. The results show that activation of FFAR1 is a viable therapeutic target for treatment of type 2 diabetes.Based on the randomised double blind controlled trial conducted between Nov 17, 2009, and Sept 29, 2010, at 95 sites in the USA, Mexico, and Guatemala.
for full article email us at mteverestnp@gmail.com
No comments:
Post a Comment